Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
Public ClinicalTrials.gov record NCT03185481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Study identification
- NCT ID
- NCT03185481
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Interventions
- 1 mg QD to 15 mg QD PF-06649751 Drug
- 3 mg QD to 15 mg QD PF-06649751 Drug
- 7 mg QD to 15 mg QD PF-06649751 Drug
- 15 mg QD PF-06649751 Drug
- 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) Drug
- 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) Drug
- 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) Drug
- 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 87 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 6, 2017 (Actual)
- Primary completion
- Oct 24, 2017 (Actual)
- Completion
- Oct 25, 2017 (Actual)
- Last update posted
- Apr 12, 2019
2017
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Associated Neurologists of Southern CT, PC | Fairfield | Connecticut | 06824 | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida | 33486 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30331 | — |
| Pharmaceutical Research Associates, Inc. | Marlton | New Jersey | 08053 | — |
| University of Toledo, Gardner-McMaster Parkinson Center | Toledo | Ohio | 43614 | — |
| University of Toledo, Investigational Drug Services | Toledo | Ohio | 43614 | — |
| The Movement Disorder Clinic of Oklahoma | Tulsa | Oklahoma | 74136 | — |
| Booth Gardner Parkinson's Care Center | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03185481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2019 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03185481 live on ClinicalTrials.gov.